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Abstract
Cadherin-17 (CDH17) is an oncofetal molecule associated with poor prognostic outcomes of hepatocellular carcinoma
(HCC), for which the treatment options are very limited. The present study investigates the therapeutic potential of a
monoclonal antibody (Lic5) that targets the CDH17 antigen in HCC. In vitro experiments showed Lic5 could markedly reduce
CDH17 expression in a dose-dependent manner, suppress b-catenin signaling, and induce cleavages of apoptotic enzymes
caspase-8 and -9 in HCC cells. Treatment of animals in subcutaneous HCC xenograft model similarly demonstrated
significant tumor growth inhibition (TGI) using Lic5 antibody alone (5 mg/kg, i.p., t.i.w.; ca.60–65% TGI vs. vehicle at day 28),
or in combination with conventional chemotherapy regimen (cisplatin 1 mg/kg; ca. 85–90% TGI). Strikingly, lung metastasis
was markedly suppressed by Lic5 treatments. Immunohistochemical and western blot analyses of xenograft explants
revealed inactivation of the Wnt pathway and suppression of Wnt signaling components in HCC tissues. Collectively, anti-
CDH17 antibody promises as an effective biologic agent for treating malignant HCC.
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Introduction
Cadherins are first identified as cell adhesion molecules with
roles in mediating cell-cell adhesion in biological processes, such as
embryogenesis, development, organogenesis and differentiation.
Recent studies have provided a strong link between tumorigenesis
and cadherin deregulation [1–4]. Frequent loss of cadherin
expression is observed in cancers especially for those cadherins
with essential function in normal physiology. E-Cadherin, the first
known cadherin molecule functioning in normal cell adhesion,
experiences loss of expression in various types of cancers in liver
[5,6] and pancreas [7]. Despite that, other cadherins are known to
involve in cancers differently. P-cadherin is another classical
cadherin that has induced expression in breast cancers [8]. Similar
to P-cadherin, N-cadherin is another notable one with overex-
pression in prostate cancers [9]. All these observations highlight
the diversified roles of cadherins in tumorigenesis.
Cadherin-17 (CDH17) belongs to the non-classical cadherin
with distinct structural feature of having seven cadherin repeats at
its extracellular amino-terminus [10,11]. Till now, Ksp-cadherin is
another cadherin found sharing similar structure with CDH17
[12]. In addition to its distinct extracellular domain, CDH17
differs from classical cadherins in having a short cytoplasmic tail at
its carboxyl-terminus [10]. No known interacting partner has been
identified for CDH17 so far, except for a possible link with
galectin-3 [11]. CDH17 was initially recognized as a peptide
transporter [13] and recent evidences uncover its other function in
cancers. The involvement of CDH17 in tumorigenesis is versatile
depending on cellular context, such that either up-regulation or
down-regulation of this molecule is found in different cancers,
including pancreatic cancers, gastric cancers and colorectal
cancers [11,14]. Indeed, this deregulated expression of CDH17
in cancers suggests this molecule as clinical indicator for disease
status and severity.
We and others have previously associated CDH17 with
hepatocellular carcinoma (HCC) [15–20]. HCC is one of the
most deadly cancers worldwide with an exceptional high rate in
Asia and Africa [21]. Because of its aggressive nature, HCC
patients usually have poor prognosis, leading to a similar
number of incidence and death [21]. Surgery including partial
hepatectomy and liver transplantation remains the frontline
treatment for patients. Most patients are first diagnosed at late-
stage and not amendable to tumor resection, while shortage of
liver grafts limits the application of liver transplantation. Even
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for those patients after surgery, tumor recurrence is common
and aggressive.
To search for new cures for aggressive HCC, we have
observed an overexpression of CDH17 in HCC tumors and this
abnormal expression is associated clinically to advanced tumor
stage and presence of venous infiltration in these patients
[15,20]. RNA interference (RNAi) was then employed to show
CDH17 possessing tumorigenic properties in HCC. We have
also treated tumor-bearing nude mice with lentivirus harboring
short hairpin RNA (shRNA) against CDH17 and this treatment
resulted in regression of developing tumor xenografts [15]. All
these data unequivocally demonstrate for the first time the
clinical potential of targeting CDH17 as a treatment for HCC.
Based on this proof-of-concept, we further develop monoclonal




Human HCC cell line MHCC97L and MHCC97H were gifts
from Shanghai Fudan University, China [15]. The human gastric
adenocarcinoma line IM95 was obtained from Japanese Collec-
tion of Research Bioresources (JCRB) cell bank. All cell lines were
cultured as described [15,22]. Cultured cells were incubated in
Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS)
(Invitrogen) and 1% penicillin-streptomycin (Invitrogen). Cultures
were maintained in a humidified atmosphere at 37uC with 5%
carbon dioxide.
Production of mAb against CDH17 from mouse ascites
The immunization of BALB/c ByJ mice with recombinant
extracellular domain 1–2 of human CDH17, fusion of antibody-
producing cells with myeloma cells, and the subsequent selection
of monoclonal hybridoma cells was performed as described
[23,24]. Clone designated as Lic5 was selected for experiments
in this study. Approval for the animal study has been obtained
from Committee on the Use of Live Animals in Teaching and
Research from The University of Hong Kong.
To prepare Lic5 for various experiments, 8-week BALB/c nu/
nu mice were injected with 500 ml paraffin oil for 7 days before
they received an intraperitoneal injection of Lic5 hybridoma cells
(56105 cells/mice in phosphate buffered saline, PBS). Ascites were
collected 7–15 days after cell inoculation, which was followed by a
second time collection 4–6 days after. Mouse ascites were
centrifuged at 12,0006 rpm at 4uC for 10 minutes and the
supernatant was collected as monoclonal antibody. Antibody was
then purified using Protein A Sepharose CL-4B (GE Healthcare,
Piscataway, NJ) and desalted using Amicon Ultra-15 Centrifugal
Filter Units (Millipore, Billerica, MA), following the protocols from
manufacturers. Lastly, the concentration of the antibodies was
estimated using RC DC Protein Assay (Life Science Research,
Hercules, CA). Silver staining was then performed to show the
purity of the antibody with procedure as described earlier [25].
The antibody immunoreactivity was confirmed using western
blotting.
In vivo efficacy study of Lic5
The anti-tumor effect of Lic5 was assessed using a murine
subcutaneous tumor model developed as described [15]. In brief,
5-week BALB/c nu/nu mice were injected with 26106
MHCC97L cells in 200 ml PBS to form subcutaneous tumors in
about 0.5 cm in diameter in 8 days. Tumor-bearing mice were
then randomly divided into different treatment groups: PBS, sterile
PBS; IgG, mouse IgG (5 mg/kg); cisplatin, 1 mg/kg cisplatin;
Lic5_L, 2.5 mg/kg Lic5; Lic5_H, 5 mg/kg Lic5; and Lic+cis, a
combined regimen of cisplatin (1 mg/kg) and Lic5 (5 mg/kg).
Treatments were administered three times weekly for 4 consec-
utive weeks by intraperitoneal injection. Body weight and tumor
size were estimated as before [15]. At the terminal time point,
tumor xenografts derived by MHCC97L were resected for western
blot and immunohistochemical staining to examine the protein
levels of CDH17, proliferation marker Ki67, retinoblastoma (Rb)
and Wnt/b-catenin pathway components. Lung tissues from all
treatment groups were also harvested and studied for any
metastatic tumors developed by means of staining with hematox-
ylin and eosin. Major organs like liver, kidney and spleen from
Lic5-treated HCC tumor-bearing mice were isolated to examine
for any signs of morphological damage after staining with
hematoxylin and eosin.
Western blotting
Procedure for western blot was performed as before [22,26]
using the following dilution of the primary antibodies: polyclonal
goat anti-CDH17 (1:000; Santa Cruz Biotechnology, Santa Cruz,
CA), monoclonal rabbit anti-b-catenin (1:1000; Cell Signaling
Technology, Danvers, MA), polyclonal mouse anti-cleaved
caspase-8 (Asp387) (1:1000; Cell Signaling), polyclonal rabbit
anti-cleaved caspase-9 (Asp353) (1:1000; Cell Signaling), polyclon-
al rabbit anti-Rb (1:200–1:1000; Santa Cruz Biotechnology) and
monoclonal rabbit anti-cyclin D1 (1:200–1:1000; Cell Signaling
Technology).
Immunohistochemistry
Immunohistochemistry was conducted as described earlier [27]
using the following dilutions of primary antibodies: anti-CDH17
(1:200), anti-b-catenin (1:200), anti-cyclin D1 (1:200), anti-Rb
(1:200) and anti-Ki67 (1:500; Abcam, Cambridge, MA).
Confocal microscopy
MHCC97H cells were seeded onto a glass-chambered slide
(Millipore) at 20,000 cells/well. After treating cells with
100 mg/mL Lic5, cells were fixed with 3% paraformaldehyde
before staining with either total or phospho-b-catenin (Thr41/
Ser45) (Cell Signaling Technology) (1:250) antibody for 1 hour.
Bound antibodies were then detected using FITC or Alexa
Fluor 488-tagged secondary antibody (1:500). Stained cells
were washed with PBS, treated with DAPI solution (0.1 mg/
mL) and monitored under confocal microscope (Nikon,
Melville, NY).
Quantitative polymerase chain reaction (qPCR)
Total RNA extraction from cell lines received treatment and the
subsequent first-strand cDNA synthesis were performed as
described [25]. Gene expression assays were performed in
duplicate using the Power SYBR Green PCR Master Mix
(Applied Biosystems, Carlsbad, CA) in a 7900HT Fast Real-time
PCR System (Applied Biosystems). Expression of the target was
normalized by GAPDH expression.
Statistical analysis
All statistical analyses on experimental data were performed
using PRISM version 4.0 for Macintosh (GraphPad, San Diego,
CA), with the significance between different groups calculated
using ANOVA, Student’s t-test, or chi-squared test in which a p-
value,0.05 was considered as statistically significant.
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Results
Lic5 targeting CDH17 reduced b-catenin level in human
HCC cells
Our previous study showed that shRNA knockdown of CDH17
inactivated Wnt/b-catenin pathway in HCC [15]. To this end, we
first examined whether Lic5, a mAb targeting the first two of the
seven extracellular domains of CDH17 (Fig. S1) would attenuate
the b-catenin signaling in metastatic human HCC cell line. We
found Lic5 treatment caused substantial reduction of CDH17
protein in a dose-dependent manner (25 to 200 mg/mL) in
MHCC97L cells (Fig. 1A). Confocal microscopy examination
further revealed that treatment of MHCC97H cells with Lic5 for
18 hours completely suppressed the cellular levels of total b-
catenin and those phosphorylated b-catenin at Thr41/Ser45,
comparing to the no treatment control (Fig. 1B). Cyclin D1 is one
of the transcriptional targets of b-catenin. We found that cyclin D1
mRNA level in Lic5-treated MHCC97H cells was significantly
suppressed at 18, 36, and 48 hours after the onset of treatment
(Fig. 1C). Notably, treatment of Lic5 was found to induce the
activation cleavage of apoptosis-related molecules caspase-8 and
caspase-9 at 18 hours and thereafter (Fig. 1D). Interestingly, a
marked reduction of CDH17 protein level was observed at
18 hour (repeated experiments yielded similar results).
Lic5 suppressed subcutaneous HCC tumor growth
We next examined whether Lic5 would suppress the growth of
subcutaneous tumors derived by MHCC97L cells in vivo.
Intraperitoneal injection of Lic5 could inhibit the growth of
subcutaneous tumors, and at the terminal time point, Lic5
antibody at both high (5 mpk) and low (2.5 mpk) dosages was
sufficient to yield .50% tumor growth inhibition (TGI) (Fig. 2A).
Strikingly, combined regimen of Lic5 and cisplatin, a chemother-
apeutic for cancer therapy, resulted in a nearly completed
abrogation (.95% TGI) on HCC xenografts. The antibody
treatment was believed to be safe because Lic5-treated mice did
not suffer significant body weight loss (Fig. S2A). No sign of
damages was observed in major/vital organs (i.e. liver, kidney, and
spleen) of the Lic5-treated mice (Fig. S2B). In addition, the anti-
tumor effect of Lic5 was similarly observed in a subcutaneous
gastric cancer model that was derived from IM95 cells (Fig. S3).
HCC xenograft sections prepared from the PBS- or IgG-treated
mice were heavily stained with the Ki67 proliferation marker
(Fig. 2B, LHS). While cisplatin lowered the Ki67-positive cells by
about 20% comparing to the PBS-treated mice, treatment with
Lic5 antibody alone could achieve a reduction by 60%,
comparable to the combined Lic+cis regimen (Fig. 2B, RHS).
Collectively, these findings indicated Lic5 is an effective thera-
peutic agent to suppress HCC tumor growth in this HCC
xenograft model, and its synergy with cisplatin or other clinically-
used chemotherapeutics warrants further investigation.
Metastatic spread of cancer cells from the primary site to lungs
is commonly seen in patients with HCC. Our animal model using
MHCC97L recapitulated the clinical observations for 83.3% (5/6)
of mice developed tumor metastasis in the lungs (Fig. 2C).
Cisplatin treatment lowered the occurrence of developing tumor
Figure 1. In vitro experiments of treating metastatic HCC cells with Lic5. Treatment of HCC cells with Lic5 inactivated CDH17/b-catenin
signaling pathway and induced apoptosis. (A) MHCC97L cells with high level of CDH17 were treated with an increasing concentration of Lic5 from 25
to 200 mg/mL. A dose-dependent reduction in the protein level of CDH17 was detected using western blot. (B) Confocal microscopy images showed
a reduction in cellular levels of total and phospho-b-catenin (at Thr41 and Ser45) proteins after Lic5 treatment in MHCC97H cells. PBS was used as a
negative control. Scale bar, 20 mm. (C) Real-time qPCR showed a time-dependent reduction of cyclin D1 gene expression level in MHCC97H cells after
treatment with Lic5 for 18, 36 and 48 hours.*, p= 0.001493; **, p= 0.00001424; ***, p= 0.00001377, when compared to the Mock (PBS) or IgG control.
Shown are the representative set of data of three independent experiments, with each column represents the mean values of triplicate data. All p-
values were calculated using ANOVA test of GraphPad PRISM. (D) Western blots showed treatment with Lic5 induced cleavage of caspase-8 and -9,
but not by the Mock and IgG controls.
doi:10.1371/journal.pone.0072386.g001
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metastasis to 66.7% (versus 83.3% for controls). Lic5 treatment
showed further reduction of lung metastasis (50% for 2.5 mpk
versus 33.3% for 5 mpk). Most strikingly, combined Lic+cis
treatment completely abrogated lung metastasis of MHCC97L
(0 out of 6 animals)(Fig. 2C), exemplifying the anti-metastatic
potential of Lic5 antibody by inhibiting the CDH17 functions in
primary HCC tumor.
Lic5 modulated Wnt/b-catenin pathway in subcutaneous
HCC tumors
We next investigated the cellular mechanism associated with the
antitumor effect of Lic5 on subcutaneous HCC tumors. As shown
by western blotting (Fig. 3A) and immunohistochemistry (Fig. 3B),
Lic5 treatment reduced the protein levels of CDH17, b-catenin
and its downstream cyclin D1 effector whereas expression of
tumor suppressor Rb protein was induced. Of note, cisplatin
treatment did not result in any major changes in the cellular level
and localization of CDH17, b-catenin, cyclin D1 and Rb in tumor
xenografts (Fig. 3A and 3B), for which cisplatin might go for
different antitumor mechanism not directly impacting the Wnt
pathway.
Discussion
Recent studies have identified CDH17 as a promising
therapeutic target for HCC treatment. In the present findings,
we further demonstrated targeting CDH17 with a mAb Lic5 could
specifically suppress the growth of CDH17-over-expressing
subcutaneous tumors by inactivating Wnt/b-catenin pathway.
Notably, the antibody treatment could markedly reduce metastatic
spread of MHCC97L cells to the lungs. mAb against cancer-
specific markers over-expressed on tumor cell surface promises an
effective strategy of anti-cancer therapy [28,29], for example,
bevacizumab and trastuzumab for breast cancer [30,31] and
cetuximab for colon, and head and neck cancers [32,33]. In
particular, trastuzumab or Herceptin that targets the human
epidermal growth factor receptor 2 (HER2)-positive breast tumors
specifically has been successfully applied in the clinics to benefit a
subgroup of cancer patients of HER2-positive cancer [31]. Thus
far effective biologics agents for clinical treatment of HCC have
not been available. Our finding suggests Lic5 would be a
promising candidate that can be further developed into a new
biological agent for potential therapy of advanced HCC.
Our previous studies have demonstrated CDH17 as an
oncofetal molecule with confirmed tumor-inducing potentials
and tumorigenic properties in HCC that Wnt/b-catenin pathway
is its downstream pathway leading to tumorigenesis [15,34]. This
study using mAb against CDH17 provided supporting evidence
showing CDH17 as an upstream molecule of Wnt/b-catenin
pathway. Here we further demonstrated that using anti-CDH17
mAb showed antitumor effects alone and in combination with
cisplatin chemotherapy regimen. Lic5 recognizes the extracellular
domain 1–2 of CDH17. The functional role of these domains has
remained unclear, however for their high resemblance with
respective structural domains of classical cadherins [35], domain
1–2 of CDH17 is believed to function in cell adhesion similar to
those of classical cadherins. Whether Lic5 would affect the cell
adhesive function of cancer cells remains to be further character-
Figure 2. Antitumor and anti-metastatic properties of Lic5 in MHCC97L xenograft mouse model. Treatment of tumor-bearing nude mice
with Lic5 inhibits tumor growth and sensitizes tumors to cisplatin. HCC subcutaneous tumors were developed in nude mice using CDH17-expressing
MHCC97L cells. Tumor-bearing nude mice were then injected with Lic5 alone, 2.5 mg/kg (Lic5_L) or 5 mg/kg (Lic5_H), or in combination of 1 mg/kg
cisplatin (Lic+cis).Mice of the control group received mouse IgG (5 mg/kg). All mice were injected three times weekly for four consecutive weeks. (A)
Sizes of the subcutaneous tumors were estimated weekly throughout the experimental period (left panel) and subcutaneous tumors were resected
28 days after the onset of treatment (right panel). Reduction in the sizes of the tumors was observed in single treatment group (Lic5 or cisplatin).
Combined regimen of Lic5 and cisplatin (Lic+cis) could result a complete inhibition on tumor growth. All p-values were calculated using Student’s t-
test of GraphPad PRISM, for which 6 tumor samples were included in each group for comparison between control and treatment groups. *, p,0.05
and ***, p,0.001. (B) The level of proliferating cells in HCC xenografts was studied using immunohistochemistry. A significant reduction in the
number of Ki67-stained cells was observed in xenografts of mice injected Lic5, alone and in combination with cisplatin. Original magnification,6400;
scale bar, 80 mm. *, p,0.01 and **, p,0.001. (C) Lic5 treatment of tumor-bearing nude mice decreases the chance of developing metastatic tumors in
lungs. Any tumors grew in lungs were spotted by staining with hematoxylin and eosin in series of sections derived from lung specimens. Treatment
of these mice using Lic5 reduced the percentage of mice having metastatic tumors in lungs and the most significant effect was observed in
combined treatment group with Lic5 and cisplatin. Chi-squared test was applied to compare control group with all other groups. *, p,0.05. Original
magnification,6400; scale bar, 40 mm.
doi:10.1371/journal.pone.0072386.g002
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ized, but our findings clearly suggested targeting the extracellular
domain of CDH17 by Lic5 can inactivate the Wnt/b-catenin
pathway. The action of Lic5 shows some degree of similarity to
other therapeutic antibodies. It has been reported that a mAb
targeting extracellular domain of N-cadherin can trigger anti-
tumorigenic response in prostate cancer cells [36]. In addition, like
ramucirumab against vascular endothelial growth factor receptor
2 (VEGFR2) [37] and trastuzumab against HER2 [38], Lic5
demonstrates its anti-cancer effect by acting on the upstream
component of signaling pathway essential to tumor progression.
Some other drugs target deregulated pathways or processes
directly and examples include those against proteasome for
protein degradation [39] and Hedgehog pathway [40]. For
HCC, a plethora of molecular-based drugs belonging to different
categories as above was under clinical trial phase for testing to be
used in clinics [41].
No matter how good the efficacy of a given anticancer agent,
other aspects like side-effects and delivery methods should be
weighted carefully before a drug can be used as a medicine for
treating patients. Importantly, the chance of tumors to develop
drug resistance should be taken into account for consideration of
long-term drug treatment. In this study, treatment of Lic5 seems to
be specific to CDH17-expressing HCC cells and xenografts only as
no significant changes in the phenotype of those cells with low level
of CDH17 and morphology of other major organs were observed
after the treatment period. Besides, the body weight loss in animals
subjected to this treatment is minimal, excluding the possibilities of
severe side-effects occurred. The next attempt for this study is to
synthesize humanized forms of these antibodies for further proof of
the concepts and confirmation of the safety profiles [42,43].
Supporting Information
Figure S1 Characterization of Lic5. (A) The high purity of Lic5
was revealed by silver staining showing two stained bands
corresponding to the light and heavy chains of the antibody. (B)
Western blot using Lic5 was performed. A 120-kDa band
corresponding to immuno-reactive CDH17 was detected in
CDH17-expressing MHCC97L cells. (C) Time-kinetic confocal
microscopy of Lic5 antibody localization against OCUM-1 cell
line. FITC-conjugated Lic5 mAb was allowed to incubate with
OCUM-1 cells at 5, 10 and 30 min in Ab/serum free DMEM
medium (1:500), washed thrice, and fixed. The green fluorescent
stain revealed strong intracellular signal of Lic5 at 30 min after
incubation, compared to the peripheral nature of the staining at
time 5 min.
(TIF)
Figure S2 Evaluation of Lic5 safety in nude mice. (A) Treatment
of tumor-bearing nude mice with Lic5 did not associate with loss
of body weight, while cisplatin treatment hampered the body
weight of mice. Combined treatment of Lic5 and cisplatin rescued
the weight loss caused by cisplatin. (B)Treatment of HCC tumor-
bearing nude mice with Lic5 does not associate with tissue damage
of major organs. Hematoxylin and eosin staining was performed in
tissue sections prepared from liver, kidney and spleen isolated from
mice treated with Lic5. No morphological damage was found in
these organs. Original magnification, 6100 (upper panel), 6200
(lower panel); scale bar, 120 mm.
(TIF)
Figure S3 Effect of Lic5 on in vivo IM95 gastric cancer model.
Gastric cancer subcutaneous tumors were developed in nude mice
using CDH17-expressing IM95 cells. Tumor-bearing nude mice
were injected with Lic5 alone (Lic5_H, 5 mg/kg), or in
combination of 1 mg/kg cisplatin (Lic+cis). Mice of the control
group received mouse IgG (5 mg/kg). All mice were injected three
times weekly for four consecutive weeks. (A) Sizes of the
subcutaneous tumors were estimated weekly throughout the
experimental period (left panel) and subcutaneous tumors were
resected 28 days after the onset of treatment (right panel).
Reduction in the sizes of the tumors was observed in single
treatment group (Lic5 or cisplatin). Combined regimen of Lic5
and cisplatin (Lic+cis) could result a complete inhibition on tumor
growth. (B) Treatment of tumor-bearing nude mice with Lic5 did
not associate with loss of body weight, while cisplatin treatment
hampered the body weight of mice. Combined treatment of Lic5
and cisplatin rescued partially the weight loss caused by cisplatin.
(TIF)
Figure 3. Lic5 treatment inactivated Wnt/b-catenin signaling in HCC tumors. Mice having MHCC97L-derived tumors were subjected to
single or combined treatment of Lic5 and cisplatin as in Fig. 2. (A) Changes in the protein level of Wnt/b-catenin pathway components like b-catenin,
cyclin D1 and retinoblastoma (Rb) in resected HCC tumors were detected using western blot. Suppression of CDH17 level using Lic5 accompanied
with an inactivation of Wnt/b-catenin pathway, leading to reduction in the levels of b-catenin and cyclin D1 and induction in the level of Rb. b-Actin
was used as a loading control. (B) Similar trend in the changes of the levels of b-catenin, cyclin D1 and Rb was observed in tissue sections of the HCC
tumor xenografts using immunohistochemistry. Original magnification,6400; scale bar, 80 mm.
doi:10.1371/journal.pone.0072386.g003
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